scholarly journals Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection

2005 ◽  
Vol 66 (1) ◽  
pp. 170-178 ◽  
Author(s):  
A OLZINSKI ◽  
T MCCAFFERTY ◽  
S ZHAO ◽  
D BEHM ◽  
M EYBYE ◽  
...  
Author(s):  
Federica Nista ◽  
Federico Gatto ◽  
Manuela Albertelli ◽  
Natale Musso

Salt intake is too high for safety nowadays. The main active ion in salt is sodium. The vast majority of scientific evidence points out the importance of sodium restriction for decreasing cardiovascular risk. International Guidelines recommend a large reduction in sodium consumption to help reduce blood pressure, organ damage, and cardiovascular risk. Regulatory authorities across the globe suggest a general restriction of sodium intake to prevent cardiovascular diseases. In spite of this seemingly unanimous consensus, some researchers claim to have evidence of the unhealthy effects of a reduction of sodium intake, and have data to support their claims. Evidence is against dissenting scientists, because prospective, observational, and basic research studies indicate that sodium is the real villain: actual sodium consumption around the globe is far higher than the safe range. Sodium intake is directly related to increased blood pressure, and independently to the enlargement of cardiac mass, with a possible independent role in inducing left ventricular hypertrophy. This may represent the basis of myocardial ischemia, congestive heart failure, and cardiac mortality. Although debated, a high sodium intake may induce initial renal damage and progression in both hypertensive and normotensive subjects. Conversely, there is general agreement about the adverse role of sodium in cerebrovascular disease. These factors point to the possible main role of sodium intake in target organ damage and cardiovascular events including mortality. This review will endeavor to outline the existing evidence.


2010 ◽  
Vol 28 (5) ◽  
pp. 952-958 ◽  
Author(s):  
William D Strain ◽  
Nish Chaturvedi ◽  
Alun Hughes ◽  
Petros Nihoyannopoulos ◽  
Christopher J Bulpitt ◽  
...  

2008 ◽  
Vol 6 (5) ◽  
pp. 731-743 ◽  
Author(s):  
Cesare Cuspidi ◽  
Carla Sala ◽  
Alberto Zanchetti

2010 ◽  
Vol 209 (1) ◽  
pp. 255-260 ◽  
Author(s):  
Vasileios F. Panoulas ◽  
Tracey E. Toms ◽  
Giorgos S. Metsios ◽  
Antonios Stavropoulos-Kalinoglou ◽  
Athanasios Kosovitsas ◽  
...  

2011 ◽  
Vol 301 (5) ◽  
pp. F1124-F1130 ◽  
Author(s):  
Steven D. Crowley ◽  
Jiandong Zhang ◽  
Maria Herrera ◽  
Robert Griffiths ◽  
Phillip Ruiz ◽  
...  

Activation of type 1 angiotensin II (AT1) receptors in the kidney promotes blood pressure elevation and target organ damage, but whether renal AT1 receptors influence the level of hypertension by stimulating sodium retention or by raising systemic vascular resistance has not been established. In the current studies, we used a kidney cross-transplantation strategy to determine whether increased sodium reabsorption by AT1 receptors in the kidney mediates the chronic hypertensive response to angiotensin II. We found this to be true. In addition, we also identified a second, nontrivial component of blood pressure elevation induced by activation of renal AT1 receptors that is sodium-independent. As the kidney has the capacity to limit the transmission of elevated systemic blood pressure into the renal microcirculation, prior studies struggled to clearly discriminate the relative contributions of blood pressure elevation vs. activation of AT1 receptors to hypertensive kidney injury. In our model, we found that rapid surges in blood pressure, which may overcome the kidney's capacity to prevent perturbations in renal hemodynamics, correlate closely with kidney damage in hypertension. Moreover, maximal kidney injury in hypertension may require activation of a pool of nonrenal, systemic AT1 receptors. These studies provide insight into precise mechanisms through which AT1 receptor blockade influences the progression of hypertensive kidney disease.


2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Speranza Rubattu ◽  
Rosita Stanzione ◽  
Massimo Volpe

Mechanisms underlying hypertensive target organ damage (TOD) are not completely understood. The pathophysiological role of mitochondrial oxidative stress, resulting from mitochondrial dysfunction, in development of TOD is unclear. The stroke-prone spontaneously hypertensive rat (SHRSP) is a suitable model of human hypertension and of its vascular consequences. Pathogenesis of TOD in SHRSP is multifactorial, being determined by high blood pressure levels, high salt/low potassium diet, and genetic factors. Accumulating evidence points to a key role of mitochondrial dysfunction in increased susceptibility to TOD development of SHRSP. Mitochondrial abnormalities were described in both heart and brain of SHRSP. Pharmacological compounds able to protect mitochondrial function exerted a significant protective effect on TOD development, independently of blood pressure levels. Through our research efforts, we discovered that two genes encoding mitochondrial proteins, one (Ndufc2) involved in OXPHOS complex I assembly and activity and the second one (UCP2) involved in clearance of mitochondrial ROS, are responsible, when dysregulated, for vascular damage in SHRSP. The suitability of SHRSP as a model of human disease represents a promising background for future translation of the experimental findings to human hypertension. Novel therapeutic strategies toward mitochondrial molecular targets may become a valuable tool for prevention and treatment of TOD in human hypertension.


2019 ◽  
Vol 20 (4) ◽  
pp. 798 ◽  
Author(s):  
Speranza Rubattu ◽  
Maurizio Forte ◽  
Simona Marchitti ◽  
Massimo Volpe

The pathogenesis of hypertension, as a multifactorial trait, is complex. High blood pressure levels, in turn, concur with the development of cardiovascular damage. Abnormalities of several neurohormonal mechanisms controlling blood pressure homeostasis and cardiovascular remodeling can contribute to these pathological conditions. The natriuretic peptide (NP) family (including ANP (atrial natriuretic peptide), BNP (brain natriuretic peptide), and CNP (C-type natriuretic peptide)), the NP receptors (NPRA, NPRB, and NPRC), and the related protease convertases (furin, corin, and PCSK6) constitute the NP system and represent relevant protective mechanisms toward the development of hypertension and associated conditions, such as atherosclerosis, stroke, myocardial infarction, heart failure, and renal injury. Initially, several experimental studies performed in different animal models demonstrated a key role of the NP system in the development of hypertension. Importantly, these studies provided relevant insights for a better comprehension of the pathogenesis of hypertension and related cardiovascular phenotypes in humans. Thus, investigation of the role of NPs in hypertension offers an excellent example in translational medicine. In this review article, we will summarize the most compelling evidence regarding the molecular mechanisms underlying the physiological and pathological impact of NPs on blood pressure regulation and on hypertension development. We will also discuss the protective effect of NPs toward the increased susceptibility to hypertensive target organ damage.


Sign in / Sign up

Export Citation Format

Share Document